title: Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome.
abstract: The cannabinoid receptors, CB1 and CB2, are expressed in the heart, but their role under pathological conditions remains controversial. This study examined the effect of CB1 receptor blockade on cardiovascular functions after experimental MI and in experimental metabolic syndrome. MI was induced in Wistar rats by permanent ligation of the left coronary artery. Treatment with the CB1 receptor antagonist rimonabant (10 mg/kg i.p. daily) started 7 days before or 6 h after MI and continued for 6 weeks. Haemodynamic parameters were measured via echocardiography and intracardiac Samba catheter. CB1 blockade improved systolic and diastolic heart function, decreased cardiac collagen and hydroxyproline content and down-regulated TGF-β1. Additionally, rimonabant decreased arterial stiffness, normalised QRS complex duration and reduced brain natriuretic peptide levels in serum. In primary cardiac fibroblasts, rimonabant decreased MMP-9 activity and TGF-β1 expression. Furthermore, rimonabant improved depressed systolic function of spontaneously hypertensive obese rats and reduced weight gain. Blocking of CB1 receptor with rimonabant improves cardiac functions in the early and late stages after MI, decreases arterial stiffness and reduces cardiac remodelling. Rimonabant also has cardioprotective actions in rats characterised by the metabolic syndrome. Inhibition of proteolysis and TGF-β1 expression and reduced collagen content by rimonabant may attenuate destruction of the extracellular matrix and decrease fibrosis after MI.
authors: Center for Cardiovascular Research (CCR) and Institute of Pharmacology, Charité-Universitätsmedizin, Hessische Strasse 3-4, 10115 Berlin, Germany.
authors: Svetlana
authors: S
authors: Slavic
authors: Dilyara
authors: D
authors: Lauer
authors: Manuela
authors: M
authors: Sommerfeld
authors: Ulrich Rudolf
authors: UR
authors: Kemnitz
authors: Aleksandra
authors: A
authors: Grzesiak
authors: Manuela
authors: M
authors: Trappiel
authors: Christa
authors: C
authors: Thöne-Reineke
authors: Johannes
authors: J
authors: Baulmann
authors: Ludovit
authors: L
authors: Paulis
authors: Kai
authors: K
authors: Kappert
authors: Ulrich
authors: U
authors: Kintscher
authors: Thomas
authors: T
authors: Unger
authors: Elena
authors: E
authors: Kaschina
mesh_terms: D000818:Animals; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006321:Heart / Q000187:drug effects / Q000502:physiology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D063387:Cannabinoid Receptor Antagonists; D002316:Cardiotonic Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D053773:Transforming Growth Factor beta1; D003094:Collagen; D020778:Matrix Metalloproteinase 2; C522363:Mmp2 protein, rat; D020780:Matrix Metalloproteinase 9; C572337:Mmp9 protein, rat; D000077285:Rimonabant
references: Cardiovasc Res. 2002 Aug 15;55(3):619-25
references: 12160959
references: Nat Rev Drug Discov. 2011 Jun 24;10(7):536-55
references: 21701502
references: J Clin Invest. 2010 Aug;120(8):2953-66
references: 20664173
references: J Am Coll Cardiol. 2007 Aug 7;50(6):528-36
references: 17678736
references: Pharmacol Rev. 2007 Dec;59(4):418-58
references: 18048761
references: J Cardiovasc Pharmacol. 2003 Apr;41(4):657-64
references: 12658069
references: Eur J Biochem. 1995 Aug 15;232(1):54-61
references: 7556170
references: FEBS Lett. 1994 Aug 22;350(2-3):240-4
references: 8070571
references: Biochem J. 2000 Mar 15;346 Pt 3:835-40
references: 10698714
references: Am J Physiol. 1999 Jun;276(6):H2085-93
references: 10362691
references: Mol Cell Biochem. 1997 Jul;172(1-2):195-8
references: 9278245
references: Biochem Pharmacol. 2005 Jun 15;69(12):1705-13
references: 15885656
references: Physiol Rev. 2007 Oct;87(4):1285-342
references: 17928585
references: FEBS Lett. 1996 Sep 16;393(2-3):231-5
references: 8814296
references: Basic Res Cardiol. 2010 Jul;105(4):465-77
references: 20361197
references: Hypertension. 2012 Feb;59(2):485-92
references: 22215717
references: J Am Coll Cardiol. 2001 Dec;38(7):2048-54
references: 11738314
references: Trends Endocrinol Metab. 2007 Jan-Feb;18(1):27-37
references: 17141520
references: Br J Pharmacol. 2003 Apr;138(7):1251-8
references: 12711625
references: Circulation. 2008 Dec 9;118(24):2523-32
references: 19029468
references: Basic Res Cardiol. 2009 Nov;104(6):781-92
references: 19462153
references: Hypertension. 2008 Oct;52(4):601-7
references: 18779440
references: Ann Thorac Surg. 2003 Feb;75(2):S644-8
references: 12607706
references: Br J Pharmacol. 2002 Mar;135(5):1191-8
references: 11877326
references: FASEB J. 2009 Jul;23(7):2120-30
references: 19246487
references: Circulation. 1995 Dec 1;92(11):3212-9
references: 7586306
references: Circ Res. 1979 Apr;44(4):503-12
references: 428047
references: N Engl J Med. 2005 Nov 17;353(20):2121-34
references: 16291982
references: J Clin Invest. 2003 Aug;112(3):423-31
references: 12897210
references: J Mol Cell Cardiol. 2010 Jun;48(6):1187-93
references: 19931541
references: Biochem Pharmacol. 2010 Jan 15;79(2):172-9
references: 19682438
references: Am Heart J. 2006 Jul;152(1):93.e1-6
references: 16824836
references: Br J Pharmacol. 2004 Mar;141(5):765-74
references: 14744801
references: J Mol Cell Cardiol. 2011 Oct;51(4):600-6
references: 21059352
references: Nat Med. 2006 Jun;12(6):671-6
references: 16715087
references: Br J Pharmacol. 2001 Feb;132(4):793-6
references: 11181418
references: Nature. 1990 Aug 9;346(6284):561-4
references: 2165569